Originally from Kyoto, Japan, Kiso graduated from Osaka Dental University in 2006 and obtained her dental license. In 2008, Kiso entered the doctoral program at Kyoto University Graduate School of Medicine and since then have been involved in tooth regeneration research under Dr. Katsu Takahashi (former associate professor at Kyoto University). In 2014, Kiso received an M.D. from the Kyoto University Graduate School of Medicine and became a member of the Department of Oral and Maxillofacial Surgery at Kyoto University Hospital. In 2016, Kiso became a Research Fellow and Clinical Practitioner at Kyoto University Hospital. In 2018, Kiso applied with Takahashi for the Kyoto University Venture Support Program (Incubation Program) and was accepted, in order to deliver the tooth regeneration antibody that Takahashi found to patients as soon as possible. In May 2020, she co-founded and became CEO of Toregem Biopharma with Dr. Takahashi and Dr. Takatani. The company derives its name from the phrase “tooth regeneration medicine.”

In 1993, Takahashi joined a pharmaceutical company as a researcher, and after a series of mergers became affiliated with Bayer Yakuhin, Ltd., where he was primarily in charge of new drug discovery and verification projects. During this time, he was also involved in regenerative medicine and iPS cell research as a senior researcher at the Kobe Research Center. Next, Takahashi served as the manager for project management and cardiovascular disease initiatives in Bayer’s development division, before being promoted to head the company’s medical affairs and primary care department. In 2014, he became the head of Bayer’s Open Innovation Center Japan. In addition to establishing the center, Takahashi led the first-ever comprehensive partnership between a foreign pharmaceutical company and Kyoto University. In 2018, he established the company's third startup incubator, CoLaborator Kobe. As a member of the Bayer Open Innovation Global Leadership Team, he has helped drive open innovation in Japan. Takahashi has been in his current position since July 2022. He holds a doctorate in science.

In 1995, Tsukahara joined The Sanwa Bank, Limited (now MUFG Bank, Ltd.). After gaining experience in the bank’s planning and large-scale corporate sales departments, he was appointed as General Manager for the Azabu branch in 2019 and Shibuya branch in 2021. During his five-year tenure as General Manager, Tsukahara supported the business growth of numerous startups, particularly SaaS-related ventures, and acquired many new business and loan transactions with startups. In April 2024, MUFG established the Startup Acceleration Strategy Division in order to further focus on supporting startups. Tsukahara was appointed as the first head of this division.

A venture capitalist who specializes in academia-based deep tech startups, Dr,Yagi promotes the founding of new companies based on the results of basic research, regardless of the business sector. His portfolio highlights include Kyoto Fusioneering, a Japanese fusion startup, and LegalOn Technologies, a leading legal tech company. He is the founder of ECC-iCAP, an entrepreneur club at Kyoto University that creates startups originating from academia. Prior to joining Kyoto iCAP, Dr.Yagi gained extensive research experience working in industry, government, and academia research institutes both in Japan and abroad. In his previous position at a major Japanese pharmaceutical company, he led the launch of new business areas.Dr,Yagi continues to pursue further education and research in the fields of chemistry and medicine.